Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis

Figure 1  PRISMA flowchart.

Figure 2 Primary endpoints. A: Weight reduction; B: Adjudicated heart failure event.

Figure 3 Adverse events. Forest plots reporting adverse events in the semaglutide group compared to placebo.

Figure 4 Other clinical and laboratory outcomes. CRP: C-reactive protein; NT-proBNP: N-terminal pro-B-type natriuretic peptide.

Figure 5 Cardioprotective actions of glucagon-like peptide-1 receptor agonists. Actions of glucagon-like peptide-1 receptor agonists on various organs and organ systems, potentially explaining the cardioprotective effect of glucagon-like peptide-1 receptor agonists. GLP-1RA: Glucagon-like peptide-1 receptor agonist.